Scarica l'app Stockscreener
284.25
1.20%
-3.45
Dopo l'orario di chiusura:
284.25
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PODD Giù?
Forum
Previsione
Precedente Chiudi:
$287.70
Aprire:
$285.51
Volume 24 ore:
588.11K
Relative Volume:
0.90
Capitalizzazione di mercato:
$20.00B
Reddito:
$2.36B
Utile/perdita netta:
$236.10M
Rapporto P/E:
86.50
EPS:
3.286
Flusso di cassa netto:
$382.50M
1 W Prestazione:
+2.19%
1M Prestazione:
-1.85%
6M Prestazione:
+0.01%
1 anno Prestazione:
+3.06%
Intervallo 1D:
$281.65
$288.12
Intervallo di 1 settimana:
$275.10
$289.25
Portata 52W:
$230.05
$354.88
Insulet Corporation Stock (PODD) Company Profile
Nome
Insulet Corporation
Settore
Industria
Telefono
978-600-7000
Indirizzo
100 NAGOG PARK, ACTON, MA
Confronta PODD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
284.25 | 20.24B | 2.36B | 236.10M | 382.50M | 3.286 |
|
ABT
Abbott Laboratories
|
121.14 | 211.73B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
359.61 | 139.12B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
BSX
Boston Scientific Corp
|
91.20 | 130.61B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
MDT
Medtronic Plc
|
98.60 | 124.05B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.46 | 48.95B | 5.88B | 1.34B | 799.60M | 2.3489 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-12 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-12-16 | Iniziato | Evercore ISI | Outperform |
| 2025-11-19 | Aggiornamento | UBS | Neutral → Buy |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Ripresa | Oppenheimer | Outperform |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-05-13 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-07 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-21 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-08-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-04 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-11 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-07-28 | Iniziato | Wells Fargo | Overweight |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Iniziato | BofA/Merrill | Neutral |
| 2020-03-31 | Downgrade | Berenberg | Buy → Hold |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-10 | Iniziato | CFRA | Sell |
| 2019-10-23 | Iniziato | Stifel | Hold |
| 2019-10-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-10-04 | Downgrade | UBS | Buy → Neutral |
| 2019-10-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-08-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-04-20 | Iniziato | Berenberg | Buy |
| 2018-02-22 | Reiterato | Barclays | Overweight |
| 2018-01-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Iniziato | Barclays | Overweight |
Mostra tutto
Insulet Corporation Borsa (PODD) Ultime notizie
VIX Spike: Is Insulet Corporation a play on infrastructure spendingRecession Risk & Fast Gain Stock Tips - baoquankhu1.vn
BVI Appoints Jim Hollingshead as President & Chief Executive Officer - GlobeNewswire Inc.
Chart Watch: What drives SWAGWs stock priceWeekly Stock Summary & Verified Trade Idea Suggestions - baoquankhu1.vn
Goldman Sachs Adjusts Price Target on Insulet to $363 From $365, Maintains Buy Rating - marketscreener.com
Nisa Investment Advisors LLC Sells 4,201 Shares of Insulet Corporation $PODD - MarketBeat
Wells Fargo Sticks to Their Buy Rating for Insulet (PODD) - The Globe and Mail
Bernstein Reduces Firm's PT on Insulet (PODD) Stock - Finviz
Bernstein Reduces Firm’s PT on Insulet (PODD) Stock - Insider Monkey
Bernstein reduces firm’s PT on Insulet (PODD) stock - MSN
Nordea Investment Management AB Has $125.13 Million Position in Insulet Corporation $PODD - MarketBeat
Insulet Corp (NASDAQ:PODD) Passes Key Growth Screen with Strong Momentum - Chartmill
Insulet Stock Is Going Off: Game-Changer For Diabetes Tech Or Just Hype? - AD HOC NEWS
Investment Recap: Will Insulet Corporation stock benefit from AI adoptionPortfolio Growth Summary & Free Real-Time Volume Trigger Notifications - moha.gov.vn
Trading Systems Reacting to (PODD) Volatility - Stock Traders Daily
Insulet Corporation (PODD) Stock Analysis: A 29.95% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Insulet Shares Fall After Barclays Downgrade - marketscreener.com
Barclays downgrades Insulet stock rating to Underweight on competition concerns - Investing.com
Insulet (PODD) Downgraded by Barclays with Lowered Price Target - GuruFocus
Barclays Downgrades Insulet to Underweight From Equal Weight, Adjusts Price Target to $274 From $316 - marketscreener.com
Barclays downgrades DexCom, Insulet as diabetes competition seen intensifying in 2 - Investing.com
Insulet (PODD) Downgraded by Barclays Amid Growing Competition - GuruFocus
Barclays Downgrades Insulet Corporation (PODD) to Underweight - StreetInsider
Insulet (NASDAQ:PODD) Downgraded to Equal Weight Rating by Barclays - MarketBeat
Aug Movers: Can Insulet Corporation ride the EV waveJuly 2025 Sentiment & High Return Trade Guides - baoquankhu1.vn
Insulin Patch Pump Market Is Going to Boom | Medtronic • Insulet Corporation • Tandem Diabetes Care - openPR.com
Why Analysts See The Insulet (PODD) Story Shifting As Omnipod Growth Meets Valuation Questions - Yahoo Finance
150,699 Shares in Insulet Corporation $PODD Bought by Parnassus Investments LLC - MarketBeat
Bernstein Lowers Price Target for Insulet (PODD) to $380, Mainta - GuruFocus
Assessing Insulet (PODD) Valuation After CES 2026 Spotlight On Omnipod 5 And Growth Prospects - Sahm
Precision Medicine and the Tubeless Revolution: An In-Depth Look at Insulet Corporation (PODD) - FinancialContent
Here's Why Insulet (PODD) is a Strong Growth Stock - Yahoo Finance
Bernstein Adjusts Price Target on Insulet to $380 From $410, Maintains Outperform Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on Insulet to $365 From $388, Maintains Buy Rating - marketscreener.com
Insulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026 - BioSpace
11,391 Shares in Insulet Corporation $PODD Purchased by Steinberganna Wealth Management - MarketBeat
Is Insulet Corporation stock a bargain at current levelsJuly 2025 Market Mood & Daily Growth Stock Tips - Улправда
Will Insulet Corporation stock outperform value stocksEarnings Trend Report & Reliable Breakout Stock Forecasts - ulpravda.ru
Trading Recap: Why hedge funds are buying Insulet Corporation stockMarket Rally & Free AI Powered Buy and Sell Recommendations - ulpravda.ru
Institution Moves: What margin trends mean for Insulet Corporation stockGap Up & Safe Entry Trade Reports - ulpravda.ru
What Provides InsuletCorp. (PODD) With a Durable Competitive Advantage? - Finviz
Pullback Watch: What margin trends mean for Insulet Corporation stockWeekly Trend Recap & Stock Market Timing Techniques - ulpravda.ru
Can Insulet Corporation stock hit record highs againTrade Entry Report & Technical Confirmation Alerts - ulpravda.ru
Can Insulet Corporation (GOV) stock resist broad market declinesWeekly Trading Summary & High Accuracy Investment Signals - ulpravda.ru
Asset Management One Co. Ltd. Has $11.86 Million Stock Holdings in Insulet Corporation $PODD - MarketBeat
Insulet’s Human‑First Omnipod 5 CES Debut Might Change The Case For Investing In Insulet (PODD) - simplywall.st
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Insulet Redefines Diabetes at CES with "Liveable Technology" — A New Frontier in Human-Centered Connected Health - Business Wire
Declining Stock and Solid Fundamentals: Is The Market Wrong About Insulet Corporation (NASDAQ:PODD)? - Yahoo Finance
How Insulet Corporation (PODD) Affects Rotational Strategy Timing - Stock Traders Daily
Is it the Right Time to Add Insulet Stock to Your Portfolio? - Yahoo Finance
Will BluEnergies Ltd 66E stock benefit from infrastructure billJuly 2025 Update & Growth Focused Entry Reports - moha.gov.vn
Insulet Corporation Azioni (PODD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.97%
1.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):